Imipramine as Third-Line Enuresis Therapy in a Home with Young Siblings
An eleven-year-old girl who has completed full, adherent trials of both alarm therapy and desmopressin without a single dry night is a genuine candidate for third-line imipramine — a drug whose real danger is measured in her four- and six-year-old brothers' bathroom, not just her own bloodstream.
Selah D., an eleven-year-old girl, has had nightly bedwetting since early childhood and has completed full, adherent trials of both desmopressin and an enuresis alarm over the past two years — six months of alarm training with documented nightly use, and a subsequent three-month desmopressin course at an appropriately titrated dose — without a single dry night on either. She is otherwise healthy, has two younger brothers, ages four and six, who share a bathroom with her, and has started declining sleepovers this year specifically because of the wetting, the first time her parents have seen her socially avoid something over it.
Having failed both International Children's Continence Society first-line options honestly, not just briefly, she is a candidate for third-line tricyclic therapy — imipramine remains the most-studied option in this role, with Caldwell and colleagues' 2016 Cochrane review of 64 trials confirming real, if modest, efficacy over placebo, but it is also the one enuresis medication where an overdose is genuinely dangerous: it blocks fast cardiac sodium channels the same way a Class I antiarrhythmic does, and doses only modestly above her own prescribed amount can produce QRS widening and ventricular arrhythmia. The FDA label caps pediatric dosing at 2.5mg/kg/day and recommends baseline ECG screening, particularly when there is any personal history of syncope or palpitations or any family history of sudden cardiac death or unstable arrhythmia — a history her family has not yet been specifically asked about. Her two younger brothers, at four and six, are exactly the age range where a found bottle of an unfamiliar medication becomes a real ingestion risk rather than a hypothetical one, which makes secure storage a genuine part of this decision rather than routine advice tacked onto the end of it.
Third-line, with two young siblings in the house
She's failed both first-line options honestly, over enough time that this isn't a compliance problem — imipramine is the appropriate next step. Before writing it, though, I want a baseline ECG and a specific family history question about sudden cardiac death or unexplained fainting, since the label flags exactly that as the scenario where this drug becomes genuinely dangerous rather than just uncomfortable.
The screening plan is right as far as it goes, but I want to name the risk more plainly before we move forward: imipramine overdose is a real pediatric poisoning cause, not a theoretical one, and it takes a comparatively small multiple of her own dose to produce cardiac toxicity in someone her brothers' size. Two children, ages four and six, sharing a bathroom with her is exactly the exposure scenario the label's storage warnings are written for, not an edge case.
I'm not arguing against imipramine categorically — only that “she's failed first-line options” answers whether the drug is indicated for her, and doesn't by itself answer whether this specific household can store it safely enough to justify starting.
You're right that the household risk is real and shouldn't be treated as an afterthought — but the answer to a real risk is a real, specific control, not withholding treatment from the child who's actually indicated for it. A locked box with an exact pill count checked at each refill is the same standard we'd apply to any other cardiotoxic medication in a home with young children, and Selah has already started turning down sleepovers over this — that's a real, present cost of further delay, not a hypothetical one weighed against a hypothetical risk.
Selah started imipramine after a normal baseline ECG and a negative family history for sudden cardiac death or unexplained syncope, with a locked storage box and a pill count checked at each refill.
Not fully agreed: how often the pill count should be checked going forward, and by whom. The pharmacologist wants it verified at every refill without exception, treated as a condition of continuing the prescription; the pediatrician sees a risk that turning it into a recurring compliance check could itself feel punitive to a child already anxious about the wetting, and would rather build in occasional spot-checks than a fixed ritual.